Clinical pipeline Leap Therapeutics is a clinical-stage biopharmaceutical company focused on oncology with ongoing development of novel therapeutics such as sirexatamab and FL-501, indicating opportunities to discuss potential collaboration, licensing, or co-development deals around early- to mid-stage assets.

PIPE funding Recent private investment activity totaling approximately $58.9 million led by notable investors presents a window for strategic engagement around future financing rounds, strategic partnerships, and potential equity-linked collaboration discussions with growth-oriented sponsors.

Public exposure Active participation in major conferences (ESMO, AACR, JPMorgan Healthcare Conference) and visible clinical data presentations provide opening for meeting scheduling, targeted outreach to research and business development teams, and timely follow-ups aligned with upcoming data milestones.

Revenue window With annual revenue in the range of $10–25 million, Leap Therapeutics sits in a mid-sized biotech segment where contract research, manufacturing partnerships, and platform-enabled collaboration opportunities could scale alongside their clinical programs.

Growth profile A lean workforce (11–50 employees) operating in biotech R&D suggests potential needs for outsourced services, CRO/CMO partnerships, data management, regulatory affairs support, and commercialization planning assistance as programs advance.